Skip to main content
johan_askling_kep.jpg

Johan Askling

Research description

Selected publications

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al Arthritis Rheum. 2009 Nov;60(11):3180-9

Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LT, et al JAMA 2012 Oct;308(13):1350-6

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. Raaschou P, Simard JF, Holmqvist M, Askling J, BMJ 2013 Apr;346():f1939

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J, Arthritis Rheum. 2012 Jan;64(1):42-52

Swedish registers to examine drug safety and clinical issues in RA. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al Ann. Rheum. Dis. 2006 Jun;65(6):707-12

Education

PhD, Karolinska Institutet

MD, Uppsala University

 

Loading bibliometrics...